CION Ameerpet
Immunotherapy · Autoimmune Disease, Transplant & Contraindications
Immunotherapy With Inflammatory Bowel Disease — Ulcerative Colitis and Crohn’s
If you live with ulcerative colitis or Crohn’s disease, you have probably been told immunotherapy is risky — often without an explanation, and often by someone who is not the doctor who would prescribe it. The honest answer is that this is the highest-risk overlap of the lot, because the organ immunotherapy most often inflames is already inflamed. That makes it a serious caution assessed case by case, not an automatic no.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Serious caution, not a blanket exclusion — ASCO, ESMO and NCCN guidance treats inflammatory bowel disease as a risk to be assessed case by case, with your gastroenterologist involved from the start.
- The bowel risk is genuinely higher — Published series report bowel problems more often when IBD is already present. How much higher is not settled — and you are owed the reason, not a one-word answer.
- Remission changes the conversation — How active your disease is now, what controls it, and how severe your worst flare was matter far more than the diagnosis label on your file.
- Decided with your gastroenterologist — A documented bowel baseline, rapid gastroenterology access and a written escalation plan are agreed before a first dose is ever given.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Can You Have Immunotherapy If You Have Ulcerative Colitis or Crohn’s Disease?
Sometimes, yes. Inflammatory bowel disease is treated as a serious caution, not an automatic exclusion. It is the highest-risk overlap in this group, because the organ immunotherapy most often inflames is already inflamed. ASCO, ESMO and NCCN guidance supports a case-by-case decision, made together with the gastroenterologist who manages your bowel disease.
That is rarely how it gets explained. Patients with ulcerative colitis or Crohn’s disease are often told immunotherapy is “not possible” with no reason attached — sometimes at a desk, sometimes by someone who is not the doctor who would prescribe it. A no reached that way is not a clinical decision. It is a guess made under time pressure.
There are also situations where the caution is real and the honest answer is no, or not yet. This page sets out how the risk is actually stratified, what is known and not known about it, what has to be in place before treatment could be considered, and what the monitoring looks like if it goes ahead.
This page is general patient education. It cannot tell you whether immunotherapy is safe for you. That assessment needs your diagnosis, your current disease activity, your medicines and your scans in front of a medical oncologist working with your gastroenterologist.
Question 1 of 3
Is the Risk of Colitis Much Higher If You Already Have IBD?
Yes, higher — that is the honest answer. Published series report bowel problems more often in patients with pre-existing inflammatory bowel disease than in patients without it. How much higher is not settled. The series are small, retrospective, and they disagree with each other.
Two different things can happen, and they get confused constantly. The first is a flare of the bowel disease you already have. The second is immune-mediated colitis, a new side effect of the treatment itself, which can happen to any patient on immunotherapy. Having IBD raises the first risk. It does not exempt you from the second. Both cause diarrhoea, urgency, cramping and sometimes blood, which is exactly why telling them apart is a job for your gastroenterologist rather than a phone call.
The evidence limit matters here. Patients with active IBD were excluded from the trials that led to approval of these treatments, so almost everything known about this overlap comes from later published series and registries rather than randomised data. Anyone quoting you a confident percentage for ulcerative colitis or Crohn’s disease specifically is ahead of what the data can support.
Severity matters as much as frequency. The concern is not only that bowel inflammation is more likely — it is that it starts from an already inflamed baseline and can be harder to bring back under control. That is why the assessment here is stricter than for autoimmune conditions affecting the skin or the thyroid; Immunotherapy With Autoimmune Thyroid Disease covers the lower-risk end of the same question.
Did you know?
Immunotherapy is given as day care at CION centres, and the appointment where eligibility is discussed is a consultation, not an infusion — nothing is started on the day you first ask about it. Bring your gastroenterologist’s latest notes, your most recent colonoscopy report and a full medicine list with doses. Also write down what your bowels are like on a normal week: every judgement made later is measured against that baseline.
Risk is stratified, not binary
Which Bowel Disease Situations Need the Most Caution?
Long-standing remission off all treatment sits at one end. An active flare, or a history of severe colitis needing hospital admission or surgery, sits at the other. Where you fall changes the monitoring plan and who has to be in the room — it rarely produces a flat no on its own.
| Your situation | How it is usually weighed | Who has to be in the discussion |
|---|---|---|
| Long-standing remission, off bowel treatment, no flare for years | Most likely to be considered. Standard immunotherapy monitoring plus a documented bowel baseline and a written escalation plan agreed before the first dose. | Medical oncologist, with your gastroenterologist informed |
| Remission maintained on ongoing bowel treatment | Often still considered. What you are taking is reviewed first — higher-dose steroids are usually reduced where the bowel disease safely allows, while maintenance treatment is not stopped casually. | Medical oncologist and the prescribing gastroenterologist |
| Mild symptoms now, disease not fully controlled | Assessed rather than assumed either way. Current activity is usually confirmed objectively before a decision, not taken from how you feel on the day. | Medical oncologist and gastroenterologist, jointly |
| Active flare, or a flare needing steroids in recent months | Usually deferred rather than refused. The flare is settled first and the decision revisited — starting mid-flare makes both problems impossible to read apart. | Medical oncologist and gastroenterologist, jointly |
| History of severe colitis — hospital admission, perforation, or bowel surgery | Highest caution of the bowel group. Considered where the alternatives are limited, with the consequences of a severe flare set out plainly and an escalation plan written down in advance. | Medical oncologist and gastroenterologist, with surgical input where relevant |
| Crohn’s disease with fistulising or narrowing complications | Weighed against how much bowel reserve there is and how quickly a complication could become an emergency. Monitoring is intensified and holding thresholds are set before starting. | Medical oncologist and gastroenterologist, with surgical input where relevant |
General patterns at guidance level only. Your own team’s assessment of your case overrides anything in this table, in either direction. If you take immunosuppressant medicines for your bowel disease, Taking Immunosuppressant Medicines and Starting Immunotherapy covers that part of the decision in more detail.
Question 2 of 3
Is Immunotherapy Ever Actually Given to Someone With IBD?
Yes, in selected patients. It is most often considered when the bowel disease is in remission, when the cancer situation makes immunotherapy the most useful option available, and when a gastroenterologist has agreed the plan. It is not offered casually, and it is not started in the middle of a flare.
When it does go ahead, certain things are in place first: current bowel activity confirmed rather than assumed, your normal stool pattern documented, existing bowel medicines reviewed by the doctor who prescribes them, a named contact for symptoms, gastroenterology access within days rather than weeks, and agreed thresholds for holding treatment written down before the first dose. If none of that has been arranged, the plan is not ready yet.
If a flare or immune-mediated colitis does happen, immunotherapy is usually held while the gastroenterology team assess and treat it. Whether it restarts afterwards is decided case by case by both teams, taking into account how severe the episode was and how well it settled. It is neither automatic nor automatically ruled out.
Not having immunotherapy is a real option and should be on the table, with the alternatives named. If the bowel risk is judged too high, the discussion should move to what else could treat your cancer — not end at a no. A decision you can live with is one where you were told what you were choosing between.
Some bowel symptoms must not be waited out or managed at home. More stools a day than your usual baseline, blood or mucus, diarrhoea that wakes you at night, new or severe abdominal pain, fever, or being unable to keep fluids down: contact your oncology team the same day, and go to the emergency department now if it is severe or getting worse. Do not start an anti-diarrhoeal medicine on your own and do not wait for the next cycle. If you cannot reach your treating doctor, call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Ask for an Assessment, Not a General Rule
A medical oncologist working with your gastroenterologist can tell you where your bowel disease actually places you, and what the monitoring plan would have to look like.
Question 3 of 3
What Monitoring Is Needed If You Start Immunotherapy With IBD?
Tighter than standard, and symptom-led. The core of it is a documented baseline of your normal bowel pattern, a named person to contact, blood tests each cycle, and rapid gastroenterology access agreed in advance rather than arranged during a crisis.
1
Your bowel baseline is documented before the first dose
How many stools you pass on a normal day, what your usual symptoms are, what your most recent colonoscopy showed, and recent inflammatory markers. Without that baseline, nobody can tell later whether anything has actually changed.
2
Your bowel medicines are reviewed, never stopped by you
Higher-dose steroids can blunt what immunotherapy is trying to do; stopping maintenance treatment can trigger the flare everyone is trying to avoid. Balancing the two is the prescribing gastroenterologist’s call, with your oncologist — see Taking Immunosuppressant Medicines and Starting Immunotherapy.
3
Specific bowel questions at every cycle, not a general one
How many stools above your baseline, any blood or mucus, any night-time diarrhoea, any new pain, any fever. “How are your bowels?” is too easy to answer with “fine” when you have lived with IBD for years and quietly recalibrated what fine means.
4
Blood tests each cycle, stool tests whenever symptoms change
Routine bloods including liver, kidney and thyroid function, because immune-related effects elsewhere can appear at the same time. If your bowels change, infection is excluded by stool testing before anything else is assumed.
5
A written escalation plan with thresholds and a phone number
Which symptoms mean call today, who to call, what is held while it is sorted out, who prescribes what, and how quickly gastroenterology will see you. If nobody has written this down, ask for it before you start rather than after something happens.
The hard part of this overlap
How Do Doctors Tell an IBD Flare From Immunotherapy Colitis?
By excluding infection first, then by pattern and timing, and where needed by looking directly at the bowel. Symptoms alone do not separate them. This is the specific difficulty that makes inflammatory bowel disease the highest-risk overlap: the target organ is already inflamed, so any change is harder to interpret.
| What it may be | Typically starts | What it tends to look like | What usually happens next |
|---|---|---|---|
| A flare of your own ulcerative colitis or Crohn’s disease | Any time; often in the first weeks, and more likely if bowel treatment was recently reduced | Your familiar pattern — the same symptoms your previous flares have had | Treated by your gastroenterologist along usual lines; immunotherapy generally held while it settles |
| Immune-mediated colitis, a side effect of the treatment | Most often in the first two to three months, commonly after the second or third dose; can appear at any time, including after treatment finishes | Rising stool frequency above your baseline, urgency, cramping, blood or mucus, sometimes fever | Treatment held; steroids or further immune-suppressing treatment under specialist supervision; endoscopy where the picture is unclear |
| Infection, including bowel infection after antibiotics | Any time, often abruptly | Sudden onset, sometimes after antibiotics, travel, or a change in food or water | Excluded by stool testing before anything is assumed to be immune-related |
| Another treatment-related or unrelated cause | Any time | Varies; may not follow your usual flare pattern at all | Reviewed by your treating team alongside the rest of your medicines |
Timing patterns come from published immune-related adverse event guidance and are general, not a rule you can apply to yourself. Any of these can appear outside its usual window, and two causes can overlap in the same person. Response-assessment scans during treatment are coordinated at partner imaging centres.
Before the consultation
What Should You Take to That Appointment?
The assessment moves much faster when the bowel half of your history arrives with you. Six things do most of the work.
- Your gastroenterologist’s most recent notes — the last consultation letter usually shows how active the disease is considered to be.
- Your most recent colonoscopy or scan report — the findings matter more than the date, but both are useful.
- A full medicine list with doses — especially steroids, maintenance treatment, and anything started in the last few months.
- A short flare history — how often, how severe, what settled it, any hospital admission or surgery. Two lines is enough.
- Your normal bowel baseline — how many stools on an average day when things are stable. This single line shapes all later monitoring.
- Your gastroenterologist’s contact details — so the two teams can speak directly instead of relaying messages through you.
You are owed a reason
Get the IBD Eligibility Question Answered Properly
Bring your gastroenterologist’s notes and your latest colonoscopy report, and get a plain answer about where your bowel disease leaves you — including if that answer is no.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy and Inflammatory Bowel Disease — Your Questions Answered
Can you have immunotherapy if you have ulcerative colitis or Crohn's disease?
Sometimes, yes. Inflammatory bowel disease is treated in current oncology guidance as a serious caution, assessed case by case, rather than as an automatic exclusion. It is the highest-risk overlap in this group, because the organ immunotherapy most often inflames is already inflamed. What matters is how active your bowel disease is now, what is controlling it, what your worst flare has looked like, and whether your gastroenterologist is part of the plan. It is most often considered when the bowel disease is in remission and the cancer situation makes immunotherapy the most useful option available. It is not started during a flare.
Is the risk of colitis higher on immunotherapy if you already have IBD?
Yes. Published series report bowel problems more often in patients with pre-existing inflammatory bowel disease than in patients without it. The size of that increase is not settled. Those series are small and retrospective, they disagree with each other, and patients with active IBD were excluded from the trials that led to approval of these treatments, so no reliable single figure exists. Severity matters as much as frequency here: inflammation starts from an already inflamed baseline and can be harder to bring back under control. That is why the assessment is stricter for bowel disease than for autoimmune conditions affecting the skin or the thyroid.
How do doctors tell an IBD flare apart from immunotherapy colitis?
By excluding infection first, then by pattern, timing and, where needed, endoscopy with biopsy. Both cause diarrhoea, urgency, cramping, and sometimes blood or mucus, so symptoms alone do not separate them. A flare of your own disease usually follows your familiar pattern. Immune-mediated colitis is a new side effect of the treatment and appears most often in the first two to three months, though it can start at any time, including after treatment finishes. Stool tests, inflammatory markers and direct inspection of the bowel make the distinction. It is made by your gastroenterology team, not over the phone.
Do you have to stop your IBD medicines before starting immunotherapy?
Not necessarily, and never on your own. Your existing bowel treatment is reviewed before anything starts, because higher-dose steroids in particular can blunt what immunotherapy is trying to do, while stopping maintenance treatment can trigger the exact flare everyone is trying to avoid. Balancing those two risks is a decision for the gastroenterologist who prescribes those medicines, working with your medical oncologist. Sometimes the conclusion is that your bowel disease cannot safely be de-escalated, and that is a legitimate clinical finding rather than a failure. Nothing here should be used to change a dose yourself.
What monitoring do you need on immunotherapy if you have IBD?
Tighter than standard, and symptom-led. Your normal bowel pattern is documented as a baseline before the first dose, because everything afterwards is judged against it. You are asked specific questions at every cycle rather than a general one: how many stools above baseline, any blood or mucus, any night-time diarrhoea, any pain or fever. Blood tests are done each cycle, with stool tests added if symptoms change so that infection can be excluded first. Rapid gastroenterology access and a written escalation plan with agreed thresholds are arranged before treatment starts, not improvised during a crisis.
What should you do if diarrhoea starts while you are on immunotherapy?
Report it the same day. Do not wait for your next cycle and do not treat it yourself. Contact your oncology team if you have more stools than your usual baseline, blood or mucus, diarrhoea that wakes you at night, new or severe abdominal pain, or fever. Go to the emergency department now if it is severe, if you cannot keep fluids down, or if it is getting worse quickly. Anti-diarrhoeal medicines bought over the counter can mask the picture and delay the treatment that is actually needed. If you cannot reach your treating doctor, call 1800 202 8726.
This page is general patient-education information, not a substitute for the written assessment your own oncology and gastroenterology teams give you for your specific case.